Germany’s Drug Price Proposal Draws Ire of Merck Chairman

The German government’s proposed changes to the nation’s drug-pricing system amount to regulatory overkill and will hurt efforts to bring drugs to market, Merck Chairman Karl-Ludwig Kley said. The proposed price restructuring would require drugmakers to prove a new drug has a superior cost-benefit ratio compared with existing treatments as a basis for price negotiations with health insurers.
International Pharmaceutical Regulatory Monitor